Tag
Paramedic-suspected STEMI identified a heterogeneous, high-acuity population where 60% had confirmed STEMI; outcomes vary by final diagnosis, underscoring the need for rapid reperfusion with early diagnostic refinement.
The BRIGHT-4 trial demonstrates that bivalirudin with prolonged infusion reduces 30-day mortality and major bleeding compared to heparin in STEMI patients undergoing radial primary PCI, benefiting both low and higher bleeding risk groups.
The CLEAN trial shows intravenous nicorandil adjunctive to primary PCI does not significantly improve 12-month clinical outcomes in STEMI. Evidence suggests microvascular benefits but no consistent long-term mortality or infarct size reduct
In Finnish adults with type 1 diabetes, STEMI and NSTEMI showed distinct incidence trends and risk profiles. NSTEMI was more common overall and linked to dyslipidemia and advanced microvascular disease, whereas impaired eGFR tracked more wi
An extensive study of 575,247 patients reveals significant improvements in hospital response times for heart attacks over the last decade, yet highlights critical gaps in care for women, elderly patients, and those admitted during off-hours
The TADCLOT trial compared ticagrelor to twice-daily clopidogrel in 2,201 STEMI patients post-PCI. While ticagrelor showed no 30-day superiority in MACE reduction, it demonstrated a significant benefit within the first two weeks with compar
A prospective study reveals that patients with mental health conditions face significant delays in STEMI diagnosis, resulting in larger infarct sizes and a twofold increase in five-year cardiovascular mortality compared to those without suc
A 20-year analysis of 89,155 patients from the SWEDEHEART registry confirms that pre-hospital delay independently predicts short- and long-term mortality. Despite advances in reperfusion, women, elderly patients, and those with diabetes con
A multicenter study identifies high-sensitivity troponin I kinetics as a diagnostic marker for hemorrhagic myocardial infarction, linking this reperfusion injury to a nearly threefold increase in the risk of in-hospital mortality following
This study validates the DanGer Shock trial criteria in a real-world registry, demonstrating that patients matching the trial’s profile have significantly better survival outcomes when treated with microaxial flow pumps compared to th
Recent substudies from the DanGer Shock trial demonstrate that microaxial flow pumps significantly improve hemodynamics, accelerate lactate clearance, and reduce vasopressor needs in STEMI-related cardiogenic shock, though sex-specific outc
This secondary analysis of the CONNECT trial demonstrates that achieving guideline-endorsed LDL-C levels significantly lowers the risk of neoatherosclerosis three years post-DES implantation in STEMI patients, underscoring the vital role of
In an international randomized trial, subcutaneous zalunfiban given at first medical contact improved pre‑PCI infarct‑related artery patency and reduced the likelihood of a worse 30‑day hierarchical clinical outcome versus placebo, with mor
The iMODERN trial demonstrates that immediate iFR-guided PCI of nonculprit lesions in STEMI patients offers no significant benefit over deferred stress MRI-guided PCI regarding major cardiac events at 3 years.
STOPDAPT-3 trial shows aspirin and clopidogrel yield comparable cardiovascular and bleeding outcomes 1 month to 1 year post-PCI in ACS patients, regardless of bleeding risk or STEMI status.
The OPTION-STEMI trial evaluated the safety and efficacy of immediate versus staged complete revascularisation during index admission in STEMI patients with multivessel disease, finding no non-inferiority of immediate approach at 1 year.
The 10-year DANAMI-3-DEFER study compared deferred stenting to immediate stenting in STEMI, showing no mortality benefit but reduced heart failure hospitalizations with deferred stenting.
This study examines the morphology of high-risk plaques in non-culprit coronary lesions among NSTEMI and STEMI patients and their impact on clinical outcomes, suggesting comparable prevalence of high-risk features but differing plaque chara
The CONNECT trial demonstrates no significant difference in neoatherosclerosis rates 3 years post-STEMI between biodegradable and durable polymer everolimus-eluting stents, challenging assumptions about biodegradable polymers’ superio
